Review Article

Immunomodulatory Effects of Mesenchymal Stromal Cells Revisited in the Context of Inflammatory Cardiomyopathy

Kapka Miteva, 1 Sophie Van Linthout, 1 Hans-Dieter Volk, 1,2 and Carsten Tschöpe 1,3,4

1 Berlin-Brandenburg Center for Regenerative Therapies, Charité, University Medicine Berlin, Campus Virchow Clinic, Südrabe 2, 13353 Berlin, Germany
2 Institute of Medical Immunology, Charité, University Medicine Berlin, Campus Virchow Clinic, Südrabe 2, 13353 Berlin, Germany
3 Department of Cardiology and Pneumology, Charité, University Medicine Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12203 Berlin, Germany
4 DZHK, Deutsches Zentrum für Herz-Kreislauf-Forschung, Berlin, Germany

Correspondence should be addressed to Sophie Van Linthout; sophie.van-linthout@charite.de

Received 18 December 2012; Accepted 13 May 2013

Academic Editor: Bruno Peault

Copyright © 2013 Kapka Miteva et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Myocarditis is a common inflammatory cardiomyopathy, associated with cardiomyocyte apoptosis, which can lead to chronic left ventricular dysfunction. Under conventional heart failure therapy, inflammatory cardiomyopathy typically has a progressive course, indicating a need for alternative therapeutic strategies to improve long-term outcomes. Experimental and clinical studies consistently support the application of cellular transplantation as a strategy to improve myocardial function. Mesenchymal stromal cells (MSCs) mediate distinct paracrine effects supporting endogenous regeneration, but most important are their remarkable immunoregulatory properties. In this review, an overview of current knowledge on immunopathology in myocarditis will be given. Furthermore, current research regarding the immunomodulatory properties of MSCs in the context of myocarditis will be discussed. Finally, the impact of MSC priming by the environment on their functionality and the advantages of systemic administration of MSCs under myocarditis are outlined.

1. Introduction

Inflammatory cardiomyopathy (myocarditis), present as an acute and/or a chronic inflammation of the heart, is associated with necrosis and degeneration of cardiomyocytes leading to subsequent cardiac dysfunction [1, 2]. Infections, systemic diseases, drugs, and toxins have been associated with the development of this disease. However, cardiotropic viruses such as Coxsackievirus 3 (CVB3) [3, 4], adenoviruses [5], and parvovirus B19 (B19) [6–8] are considered to be the main cause of inflammatory cardiomyopathy.

The pathology of viral inflammatory cardiomyopathy results from the concomitant work between viral processes of propagation and the host immune responses in attempt to resist and fight against the virus. Both innate and adaptive immune responses are crucial determinants of the severity of myocardial damage, often associated with autoimmune responses against the heart tissue antigens. The overwhelming immune response contributes to the development of chronic myocarditis and dilated cardiomyopathy (DCM), a condition for which the only treatment option at end-stage is heart transplantation [9]. DCM is one of the most common causes of heart failure, contributing to the main mortality rate of cardiomyopathy [10]. Although the application of modern therapy options has led to improved mortality rate, only half of the patients survive for five years [11]. Immunosuppressive and immunomodulating therapy have shown a beneficial effect in chronic, virus-negative inflammatory cardiomyopathy [12, 13], while there is evidence that antiviral therapies [14–17] and antimicrobial agents [18] may have a therapeutic effect in viral or bacterial-induced myocarditis, respectively. Although prominent progress in elucidating the pathophysiological mechanisms of myocarditis and establishment of
treatment strategies has been made during the last years, a universal treatment standard is still not available.

There is accumulating evidence supporting cell therapy as novel treatment option for cardiovascular disorders. MSCs have the advantage over other cells to have a low immunogenicity, allowing unmatched allogenic off-the-shelf MSCs have the advantage over other cells to have a low apy as novel treatment option for cardiovascular disorders. universaltreatmentstandardisstillnotavailable.

treatment strategies has been made during the last years, a dying necrotic and apoptotic myofibers[20].

the infiltration of host immunecells, releasing cytokines and by autoimmune and inflammatory mechanisms, leading to inflammation is a leading component and a dominant mechanism in the pathogenesis of inflammatory cardiomyopathy, which is further corroborated by the finding that extensive inflammation in patients with acute myocarditis is an independent predictor of negative outcome [22]. On the other hand, the inflammatory response occurs as a natural defense of the virus-infected heart and plays an important role in pathogen elimination, healing, and tissue repair. However, when the inflammatory response is inadequate and overwhelming, it becomes the cause of a direct injury of cardiac cells and of indirect damage through the action of proinflammatory cytokines and anti-cardiac autoantibodies, affecting the function of the cardiomyocytes. Therefore, it is not surprising that several preclinical studies have found a beneficial effect of an anti-inflammatory therapy applied during myocarditis [23-26].

The evolution of viral myocarditis can be divided in three phases: an acute viremic phase marked by an active replication of live virus within the myocardium. The second phase is a subacute phase characterized by the persistence of the viral genome without detectable viral replication, but with substantial heart infiltration of mononuclear cells. Remodeling in the absence of replicating virus or viral genome defines the chronic phase of viral myocarditis [27].

Current understanding of the pathogenesis and the mechanism of myocarditis progression to heart failure, particularly the interaction of inflammatory cells with the cells of the myocardium, is largely based on experimental models using susceptible (A.BY/SnJ and SWR/J) and resistant (C57BL/6J and DBA/JJ) mouse strains infected with the cardiotropic virus CVB3.

2.1. Role of the Innate Immune System in Myocarditis. A broad panel of pattern recognition receptors of the innate immune system and cardiac Toll-like receptors (TLRs) sense viral pathogen-associated patterns [28, 29]. Subsequently, the cells endogenous to the heart—cardiomyocytes, endothelial cells, fibroblasts, and dendritic cells activated via TLRs—respond to the virus infection by releasing cytokines including interleukin (IL)-1α, IL-1β, IL-6, IL-18, tumor necrosis factor (TNF)-α, TNF-β, and interferon (IFN)-γ [30, 31]. TLR4 expression is prominently increased in endomyocardial biopsies of myocarditis patients and is associated with enteroviral replication and cardiac dysfunction [32].

With respect to inflammatory cardiomyopathy, type I and II IFN activation is known to play an essential cardioprotective role against CVB3 infection. Especially IFN-γ expression protects against lethal infections by inducible nitric oxide synthase (iNOS) induction in macrophages and by mediating viral load reduction. Furthermore, experimental and clinical studies have demonstrated that IFN-β can lead to elimination of the viral genome and to an improvement of LV function [16, 17, 31, 33, 34].

Natural killer (NK) cells are the first immune cells which infiltrate the myocardium and mediate a cardioprotective effect by limiting the virus replication [35]. However, in spite of the quantitative increase in NK cells subpopulations in the myocardium of patients with cardiomyopathy, functional abnormalities exist in those subpopulations, which are probably related to the pathogenesis of myocarditis [36].

In addition to the infiltrated NK cell, various cytokines are produced at that stage, including IL-1α, TNF-α, IFN-γ, and IL-12 in patients with acute myocarditis is an independent predictor of negative outcome [22]. On the other hand, the inflammatory response occurs as a natural defense of the virus-infected heart and plays an important role in pathogen elimination, healing, and tissue repair. However, when the inflammatory response is inadequate and overwhelming, it becomes the cause of a direct injury of cardiac cells and of indirect damage through the action of proinflammatory cytokines and anti-cardiac autoantibodies, affecting the function of the cardiomyocytes. Therefore, it is not surprising that several preclinical studies have found a beneficial effect of an anti-inflammatory therapy applied during myocarditis [23-26].

The evolution of viral myocarditis can be divided in three phases: an acute viremic phase marked by an active replication of live virus within the myocardium. The second phase is a subacute phase characterized by the persistence of the viral genome without detectable viral replication, but with substantial heart infiltration of mononuclear cells. Remodeling in the absence of replicating virus or viral genome defines the chronic phase of viral myocarditis [27].

Current understanding of the pathogenesis and the mechanism of myocarditis progression to heart failure, particularly the interaction of inflammatory cells with the cells of the myocardium, is largely based on experimental models using susceptible (A.BY/SnJ and SWR/J) and resistant (C57BL/6J and DBA/JJ) mouse strains infected with the cardiotropic virus CVB3.
DCs maturation/activation and DCs MHC class I antigen processing is associated with failure in viral clearance leading to ongoing chronic disease [47].

2.2. Role of the Adaptive Immune System in Myocarditis. In the subacute stage, cardiac infiltrating macrophages, DCs, and T cells not only contribute to ongoing cardiac dysfunction [48], but the release of a great variety of cytokines triggers a second wave of immune cells infiltration, including antigen-specific CD4+ and CD8+ T lymphocytes and B cells.

A pioneer study has defined the prominent role of T cells in the pathogenesis of viral myocarditis, demonstrating that virus infected T-cell-deprived BALB/c mice are protected against lethal infection and exhibit significantly diminished cardiac inflammation [23]. This observation was further confirmed in a more complex study showing that elevated IFN-γ and decreased TNF-α expression are associated with attenuated myocardial damage in CD4−/−CD8−/− mice [49]. Moreover, those findings indicate that T-cell subsets influence the pathogenesis of myocarditis via modulation of the cytokine expression patterns. Furthermore, cardiac damage in B19-induced myocarditis has been shown to be mediated not only by the primary viral infection and replication within cardiac endothelial cells leading to ongoing vascular injury and subsequent chronic endothelial damage [17], but also via CD8+ T cells directed against the myocardium [50]. Furthermore, exacerbated perforin expression in endomyocardial biopsies from patients with acute myocarditis indicates that T lymphocytes might cause a direct cell-mediated cytotoxicity and might injure the myocardium [51].

Patients with myocarditis exhibit an imbalance between helper and cytotoxic T cells [52], providing further evidence that T-cell subpopulations play a great role in the pathogenesis of myocarditis. A recent study in patients with cardiomyopathy revealed a reduced activation of T helper type 1 (Th1) cells producing IFN-γ and an impaired production of IL-10, known as a major regulatory cytokine, downregulating an over-enhanced immune response [53]. Those abnormalities in the adaptive immune response could explain to a certain extent the autoimmune features of myocarditis. The cardioprotective role of IL-10 is evident by its ability to reduce proinflammatory cytokines, such as IFN-γ, TNF-α, and IL-2, in experimental autoimmune myocarditis [54, 55]. Notably, intravenous (i.v.) immunoglobulin treatment of patients with DCM resulted in a significantly increased IL-10 level, which was paralleled by a prominent improvement of left ventricular ejection fraction [56].

In the recent years, the concept that the Th1 cytokine IFN-γ has regulatory functions and influences the autoimmune reaction has been proven in experimental autoimmune myocarditis, where IFN-γ deficiency resulted in the development of exacerbated myocarditis and fatal autoimmune disease [57, 58]. IFN-γ is a proven inducer of FoxP3 and the conversion of CD4+CD25+ T cells into CD4+ regulatory T cells (Tregs), in both mice and humans [59]. IFN-γ is also shown to reduce the progression to chronic myocarditis and DCM via increasing the CD4+CD25+ T regulatory population and reducing fibrosis and pericarditis [60, 61].

Moreover, patients with DCM exhibit increased numbers of peripheral Th17 cells associated with autoimmune diseases [62–64] and upregulated levels of the proinflammatory cytokines IL-17, IL-6, and IL-23 [65].

Activated T cells promote clonal expansion and differentiation of B cells, resulting in further injury of cardiomyocytes, enhancement of the local inflammation, and production of circulating antiheart antibodies [66]. It has been widely accepted that viral myocarditis can progress to idiopathic DCM as a consequence of an autoimmune reaction [67, 68]. The percentage of patients with histologically proved myocarditis and serum autoantibodies is ranging from 25 percent to 73 percent [69]. In patients with DCM, autoantibodies have been identified that react with heart mitochondria [70], the adenine nucleotide translocator [71], the muscarinic receptor [72], cardiac troponins [73], myosin heavy chain [74], the second extracellular loop of the betadrenergic receptor [75], and others [76].

In summary, evidence from experimental and clinical studies states the complex interactions between distinct immune cells during the different stages of the pathogenesis of myocarditis. This underscores the importance of characterizing the stage of the pathogenesis of myocarditis via endomyocardial biopsy analysis [77, 78] to enable an efficient therapy.

3. Immunomodulatory Effect of MSCs

Over the past five years, multipotent MSCs have attracted considerable attention, due to their unique immunoregulatory and regeneration supporting properties. Our understanding about the mechanisms of MSC-mediated immunomodulation has been significantly advanced, and MSCs have found a broad application in the fields of inflammatory-mediated disorders and cell therapy. MSCs have a profound effect on components of both innate and adaptive immune response. Numerous reports indicate that the soluble factors released by MSCs induce anergy, apoptosis, Treg cells as well as regulatory (“tolerogenic”) macrophages, and dendritic cells. A particularly important aspect of MSC-mediated immunomodulation is their capacity to migrate to the site of inflammation where the local microenvironment initiates the activation of the MSCs immunomodulatory action, resolving the inflammation.

MSCs have first been isolated from the bone marrow and identified as colony-forming-unit fibroblasts (CFU fibroblasts) [79]. MSCs are a heterogeneous population of cells that possess stem cell-like characteristics including self-renewal and differentiation capacities in vitro [80]. MSCs are predominantly located in perivascular niches and can be found in nearly all tissues. They have been derived from adipose tissue [81], peripheral blood [82], lung [83], placenta, or heart [84]. We recently have isolated and identified novel cardiac-derived cells from endomyocardial biopsies: CardAP cells, previously called CAPs, which show similarities with MSCs [85] and comparably exhibit antiapoptotic [86], proangiogenic, and antifibrotic properties (unpublished data). Among those others, they exhibit
prominent immunomodulatory and antiviral features [86, 87]. They reduce the induction of immune cell proliferation, decrease the cardiac levels of TNF-α, and not only elevate the proportions of Tregs [86, 87] but also reduce the proportion of apoptotic Tregs in CVB3-infected mice [86]. Similar to MSCs, CardAPs exert their immunomodulatory effects in a paracrine as well as in a cell-contact-dependent manner (Figure 1).

The next subparagraphs are focused at giving an overview of the MSC-mediated immunomodulatory effects. Besides the established impact of MSCs on the adaptive immune response, also their less documented influence on the innate
immune response, which plays a leading role in the induction of inflammatory diseases [88], including autoimmune myocarditis [89], will be discussed.

3.1. Effect of MSCs on Macrophages. Resident macrophages are known to initiate inflammation in most tissues [90]. Macrophages not only have a great plasticity and can be polarized from classically activated M1 proinflammatory macrophages to alternatively activated M2 anti-inflammatory macrophages, but they also play a key role at the sites of inflammation [91, 92] and determine the severity of inflammation [93, 94]. MSCs mediate the switch of the macrophage phenotype in a cell-contact-dependent manner via binding of prostaglandin E2 (PGE-2) released by MSCs to PGE-2 receptors on macrophages [93, 95, 96] and/or in a paracrine manner via the release of indoleamine 2,3-dioxygenase (IDO) [94]. Moreover, the proinflammatory microenvironment, containing alloreactivated T cells [97] and IFN-γ, TNF, LPS [94, 95], promotes MSC activation via TLR4 and TNFR1 leading to the activation of nuclear factor-κB (NF-κB) signaling and subsequent expression of cyclooxygenase 2 and IDO in MSCs, which further induces macrophages polarization to the M2 type [97]. Importantly, the MSC-mediated protective effect has been shown to be abrogated after macrophage depletion or anti-IL-10 neutralizing antibodies application, furthermore highlighting the relevance of MSC-mediated reprogramming of macrophages, preventing excessive inflammatory responses and supporting tissue regeneration [95]. The ability of MSCs to induce M2 macrophages is of great relevance for resolving the inflammation and for the prevention of the development of autoimmune myocarditis not only due to the release of the anti-inflammatory and cardioprotective cytokine IL-10 [54, 95] but also due to the critical role of M2 macrophages in the induction of Treg cells in myocarditis [55]. In addition, the anti-inflammatory protein TNF-stimulated gene-(TSG-6) secreted by activated MSCs has been shown to attenuate peritonitis by decreasing TLR2/NF-κB signaling in resident macrophages [98]. Another paracrine factor involved in the interaction of MScs with macrophages is the IL-1 receptor antagonist, which is released by MSCs and abrogates the secretion of TNF by activated macrophages [99].

3.2. Effect of MSCs on Natural Killer Cells. MSCs inhibit not only the cytokine-induced proliferation of freshly isolated NK but also their cytotoxic function [100], cytokine production, granzyme B release, and activating receptors expression [101–105]. They inhibit the function of NK cells mainly in a contact-dependent manner and to a lesser extent by the release of paracrine factors such as IDO and TGF-β [105–107]. Since NK cells are important effector cells with cardioprotective properties, limiting virus replication [35] through the release of IFN-γ [108], an MSC-mediated repressive effect on NK cells at an early stage of infection when NK cells play an indispensable role in the inhibition of the viral replication [35] could favor viral propagation and exacerbation of autoimmune myocarditis. This hypothesis is supported by the finding that functional abnormalities of NK [36] or NK cells depletion [109] contributes to the pathogenesis of myocarditis. On the other hand, overactivation and/or long-term presence of NK cells may abrogate the myocardial damage due to the excessive release of cytotoxic molecules such as perforin within the myocardium, known to contribute to myocardial necrosis and lymphocyte infiltration [110]. Therefore, the MSC-mediated inhibitory effect on NK function in the case of overactivation and NK cells persistence in the myocardium could be beneficial for resolving the inflammation and diminishing the myocardial damage.

Overall, the consequence of the MSC-mediated suppressive effect on NK function strongly depends on the stage of myocarditis. Via their suppressive effect, they could either support viral propagation in the viremic phase or could be beneficial reducing myocardial damage, decreasing the inflammation in the subacute phase.

3.3. Effect of MSCs on Dendritic Cells. MSCs have a profound effect on DCs which perform antigen acquisition, processing, and antigen presentation to naive T cells and are therefore of crucial importance for the direction of the development of the adaptive immune responses. Importantly, MSCs can influence the phenotype of the DCs, diminishing the percentage of DCs with a conventional phenotype, while promoting the plasmacytoid DCs, directing hereby the adaptive immune response towards the Th2 type [111]. Importantly, this MSC-mediated induction of plasmacytoid DCs and subsequent development of a Th2 response is of great relevance in the context of myocarditis due to the protective effect of the Th2 polarization preventing the development of autoimmune heart disease [112, 113]. Moreover, the MSC-mediated induction of plasmacytoid DCs which are a source of type-I IFN further exerts direct antiviral effects [113]. In addition, plasmacytoid DCs upregulate the release of the anti-inflammatory and cardioprotective cytokine IL-10 in the presence of MSCs [107], which could further protect against an overwhelming immune response and cardiac damage. Besides influencing the DC phenotype, MSCs inhibit DCs differentiation, maturation, and impair the antigen-presenting function of the DCs [114–116]. Moreover, several studies have demonstrated that MSCs interfere with the capacity of DC to migrate to the local lymph node [117], which further significantly affects the ability of DCs to prime T cells in the draining lymph. It will be of great interest to define the effect of MSC application on the migration and homing capacity of DCs in the context of myocarditis.

3.4. Effect of MSCs on the T-Cells Balance (Th1/Th2/Th17/Thregs). T cells are a major player in the adaptive immune response. They are activated through the TCR receptor proliferate and perform numerous effector functions, including
cytokines release and inducing cytotoxicity in case of CD8+ T cells (CTL), which all contribute to cardiac damage [118]. Numerous publications have shown that MSCs successfully inhibit T-cell proliferation in vitro and in vivo [119–125]. In addition, MSCs are able to induce T-cells apoptosis, and a very recent study has revealed the exact mechanism demonstrating that after systemic infusion of MSCs, T cells underwent apoptosis via the FAS ligand-dependent FAS pathway [126]. In agreement with this finding, we have shown that the application of MSCs as well as of the MSCs-like CardAPs results in MSCs/CardAPs-induced apoptosis of CD4+ and CD8+ T cells in a model of CVB3-induced inflammatory cardiomyopathy [86, 127].

Moreover, MSCs exert a systemic suppressive effect by mediating a polarization of the host immune response towards a Th2 profile, independently from Tregs induction [128], which precludes the development of an autoimmune heart disease [112]. Furthermore, MSCs not only promote a dominant Th2 phenotype but also decrease the pro-inflammatory cytokines IL-17 and IFN-γ and increase the levels of IL-4, IL-10, and TGF-β in models of autoimmune disease [129, 130]. Interestingly, we have found that in a model of viral-induced myocarditis, application of MSCs [127] and CardAPs [86] promotes the upregulation of IFN-γ, known to reduce CVB3 replication [131]. Additionally, CVB3-infected mice receiving either MSCs or CardAPs had elevated cardiac mRNA expression levels of IL-10, and MSCs-treated mice had significantly higher proportion of IL-10-producing CD4+ and CD8+ T cells [127], which leads to diminished severity of the disease. Importantly, both IL-10 [132] and IFN-γ [133] are crucial in the functionality of Tregs. Another cytokine involved in Treg cells induction is TGF-β, which is released during the process of macrophage phagocytosis of the apoptotic T cell, which had gone to apoptosis after MSCs application [126].

In addition, MSCs inhibit the formation of CTL but preserve the activated CTL with a restricted killing of virally infected cells [102]. This balanced effect of MSCs allowing a precise killing of virally infected cells is of great benefit restricting the CTL activity only on virally infected cells and preventing the damage of healthy cardiomyocytes.

In several immune-mediated diseases, the transfer of MSCs has been accompanied by a decrease in Th17 cell activity, leading to a significant disease improvement [128, 134]. Moreover, MSCs not only efficiently suppress the production of the proinflammatory cytokines IL-17 and IL-22 by Th17 cells but also could reprogram Th17 cells into IL-10+ FoxP3+ Treg cells [135]. In addition, human and mouse MSCs prevented the de novo generation of Th17 cells from naïve T cells [136].

Tregs play an essential role in the regulation of the immune responses and in the prevention of autoimmune disease. MSCs-induced tolerance is often associated with a promotion of Tregs [137–139]. The importance of Treg cells for the immunomodulatory effect of MSCs is evident from studies showing that a depletion of Tregs abrogates the anti-inflammatory effect mediated by MSCs [139, 140]. As previously discussed, MSCs favour the generation of Tregs, and this corresponds with a decrease in Th1, Th2, and Th17 lymphocytes [126, 129, 135, 141]. It has been shown that MSCs could promote Treg cells in a contact-dependent manner [142] as well as by releasing PGE-2 and TGF-β1 [143]. MSC-mediated expansion or induction of Treg cells has been associated with beneficial effects in a number of alloreactive, autoimmune, and allergic diseases including organ transplantation [137, 138, 144, 145], type 1 diabetes, [130, 146] and inflammatory bowel disease [126, 147] as well as acute CVB3-induced myocarditis [127]. The protection afforded by MSCs in these models is mediated through multiple mechanisms, which in the end lead to the generation of functionally active Tregs and subsequent establishment of an immune tolerance. Although the number of transplanted MSCs, which initially suppress the pathogenic Th2 phenotype, decreases over time, MSC-induced Tregs expand and persist and could be the key cells establishing a sustained immune control long after MSCs have disappeared [148].

Both cell-cell contact and soluble factors have been implicated in MSC-mediated immunosuppression. It has been shown that IFN-γ acts directly on MSCs and leads to the upregulation of B7 homolog 1 (B7-H1), known to function by interaction with its cognate receptor on target cells, a process mediated by cell-cell contact and facilitating MSCs-induced inhibition of lymphocyte proliferation [149]. In line with this notion, we have found that CardAPs similarly to MSCs upregulate the expression of B7-H1 upon IFN-γ stimulation (Figure 1(a)), and B7-H1 knockdown of CardAPs abolished the antiproliferative effects on activated splenocytes (Figures 1(a) and 1(b)). The described finding suggests that the immunomodulatory effects of CardAPs are at least partly mediated in a contact-dependent manner via B7-H1 interaction.

Several soluble immunosuppressive factors are either produced constitutively by MSCs or released by MSCs upon activation and contribute to the immune-regulation. For example IDO is only released by MSCs after IFN-γ stimulation [150, 151]. However, the soluble factors TGF-β1, hepatocyte growth factor [152], IL-10, PGE-2, haem-oxygenase-1, and IL-6 are constitutively produced by MSCs [153, 154].

Human leukocyte antigen-G5, which is also constitutively produced by MSCs, suppresses T-cell proliferation, as well as NK cell and T-cell cytotoxicity, while promoting the generation of Tregs [142] is another relevant factor for the MSC-mediated regulation of the immune response. Furthermore, MSCs have been shown to express the anti-inflammatory protein TSG-6 upon engraftment in the lung and subsequent activation after i.v. injection in a myocardial infarction model. This MSC-mediated release of TSG-6 suppressed the excessive inflammatory response in the heart, resulting in improved cardiac function and diminished scarring of the left ventricle [155].

None of the previous paracrine factors released by MSCs seems to have an exclusive role in the MSC-mediated immune regulation, which is probably a result of a combination of mechanisms.
3.5. Effect of MSCs on B Cells. B cells are central contributors to the pathogenesis of immune-related disorders [156] and particularly of myocarditis [157], due to their ability to produce antibodies as well as their role in antigen presentation, modulation of the spleen architecture, and Th1/Th2 polarization of T cells [156]. On the other hand, a distinct regulatory B-cells (Bregs) subset with suppressive functions, including inhibition of Th1-, Th17-, or induction of Th2-mediated responses, conversion of effector T cells into IL-10-producing T cells, and maintenance of FoxP3 expression in the Treg pool, has been identified and studied [158, 159]. Knowing that MSCs promote the generation of Tregs [137–139], it will be of interest to investigate whether MSCs can also promote Bregs, which could exert a great variety of immunomodulatory effects and consequently could also be beneficial in resolving the inflammation in myocarditis. The immunomodulatory properties of MSCs also include a direct effect on B-cell activities. MSCs inhibit B-cell proliferation and terminal differentiation [160] to immunoglobulin IgM-, IgG-, and IgA-antibody secreting cells and B-cell chemotaxis [161]. The finding that MSCs injected in vivo home to lymph nodes and the spleen where they cluster around T cells [162] supports the hypothesis that B cells may also be targeted by MSCs in the T-cell area of secondary lymphoid organs. Subsequently, this effect could be beneficial in the subacute stage of myocarditis, preventing the induction of a second wave of immune cell infiltration, including antigen-specific CD4⁺ and CD8⁺ T lymphocytes.

4. Priming of MSCs

The view that MSCs require priming or activation in order to fulfill their immunosuppressive function is already a well-established concept. It has been repeatedly demonstrated that IFN-γ, TNF-α, or IL-1β are the essential factors necessary for MSCs activation and the subsequent induction of immunomodulatory effects [150, 163, 164]. In agreement with those findings, our research revealed that MSCs require IFN-γ priming to exert their antiapoptotic, antioxidative, and antiviral features, and the supplementation of IFN-γ to CVB3-infected MSCs increased nitric oxide (NO) production. This suggests that in the context of CVB3 and upon activation with IFN-γ, MSCs produce NO via which they exert their antiapoptotic and antioxidative effects, leading to a decrease in viral progeny release and viral production [127]. Importantly, it has been shown that MSCs derived from IFN-γ receptor deficient mice have lost their immunosuppressive activity, which highlights the exclusive role of IFN-γ in the immunosuppressive function of MSCs [163]. Moreover, we found that CardAPs require priming via IFN-γ in order to exert their antiapoptotic and immunomodulatory features too, and upon IFN-γ supplementation, CVB3-infected CardAPs raised significantly the level of the anti-inflammatory cytokine IL-10 [86]. The importance of IFN-γ priming for the functionality of MSCs/CardAPs on the one hand and the increased cardiac IFN-γ levels in acute CVB3-induced myocarditis on the other hand [127] support the hypothesis that MSCs/CardAPs will exert their protective effects in the cardiac inflammatory environment of acute CVB3-induced myocarditis. Furthermore, the induction of cardiac IFN-γ mRNA expression upon MSCs/CardAPs application suggests an autonomous self-regulatory feedback loop ensuring the activated state of MSCs/CardAPs [86, 127].

Interestingly, MSCs derived from different sources have been reported to express TLR 1, 2, 3, 4, 5 [165–169]. The inflammatory environment has a great influence on the TLRs expression pattern in MSCs, and the proinflammatory cytokines IFN-α, IFN-γ, TNF-α, and IL1-β promote TLR 2, 3, and 4 expression while downregulate TLR 6 expression [170]. Moreover, TLR signaling in MSCs has also been implicated in the priming of MSCs. For example, TLR 3 and TLR 4 activation of MSCs provoked an MSC-mediated immunosuppression via IDO induction and IFN-β and protein kinase R signaling [171], while TLR 2 activation of MSCs resulted in the upregulation of the immune-suppressive protein galectin-3 [172]. By contrast, another study demonstrated that MSC activation through TLR 3 and 4 resulted in the loss of the immunomodulatory effects of MSCs via downregulation of Jagged-1 [173]. Overall, TLR signaling has the capacity to convert MSCs to cells with a proinflammatory and antigen-presenting phenotype, releasing proinflammatory cytokines and chemokines, which further promote inflammation [174]. In line with the previous observations, Waterman et al. proposed the idea that the induction of proinflammatory (MSC1) or anti-inflammatory (MSC2) phenotypes of MSCs depends on the ligand concentration, the timing, and the kinetics of activation [175]. For example, TLR 4 activation results in the upregulation of the classical proinflammatory cytokines IL-6, IL-8, or TGF-β (MSC1 phenotype) and activation of T lymphocytes, while TLR 3 priming results in the production of anti-inflammatory molecules like IL-4, IDO, or PGE2 (MSC2 phenotype) and inhibition of lymphocyte proliferation [175].

Further investigation is required on the effects of TLR activation on MSCs. However, these findings indicate that MSCs are cells with a great plasticity, which is modulated by the factors of the environment, and point out that MSCs may have the capacity to promote pathogen clearance or immune suppression as well as inflammation.

5. Route of Application

Whereas the low cardiac engraftment of MSCs after i.v. injection compared to intracoronary or endocardial application is well established [176], only recent studies have indicated the potential benefit of extracardiac targeting of MSCs for the cardiac outcome. Lee et al. [155] demonstrated that MSCs upon entrapment in the lung after i.v. injection expressed the anti-inflammatory protein TSG-6 and improved myocardial infarction via—at least in part—the release of this anti-inflammatory protein. This followed from the finding that MSCs transduced with TSG-6 siRNA did not exert these protective effects, whereas i.v. application of recombinant TSG-6 also did. The same authors [177] further demonstrated in a chemical injury model of the cornea that systemic administration of MSCs reduced inflammatory damage to
the cornea without engraftment, underscoring their mode of action at a distance. Kavanagh and Mahon [140] provided evidence that i.v. MSC application prevents allergic airway inflammation by inducing murine Tregs following from the finding that under the use of a moderate dose of cyclophosphamide to differentially ablate Treg responses, the major beneficial effect of MSC therapy was lost. With respect to CVB3-induced myocarditis, we demonstrated that both i.v. application of MSCs [127] and of CardAPs [86] resulted in an induction of Tregs, whose protective effects in myocarditis have been consistently demonstrated [60, 61] and in a raise of splenic apoptotic CD4\(^+\) and CD8\(^+\) T cells. With the spleen being a reservoir of monocytes, which are recruited to the inflammatory heart [178], we suggest that these MSC/CardAPs-mediated immunomodulatory effects in the spleen contributed to the cardioprotective effects of MSCs/CardAPs in inflammatory cardiomyopathy. This hypothesis is supported by the findings that (i) splenectomy improves the myocardial infarction outcome [179], (ii) the use of an antibody against T cells reduces the cardiac damage in myocarditis [180], and (iii) our recent observation that splenocytes isolated from CVB3-infected mice injected with MSCs induce less collagen production in fibroblasts compared to splenocytes from CVB3 mice [127].

The limited number of cardiac engrafted MSCs after i.v., intracoronary, and endocardial application [127, 155, 176], their limited residence time [155], and their action into their near proximity upon engraftment [163] suggest that the improvement in cardiac function after application cannot be solely due to the cardiac engrafted MSCs and further supports the significance of the beneficial effects of extracardiac targeting, be it by the induction of paracrine factors and/or of Tregs. Figure 2 represents a hypothetical scheme of how MSCs or the MSC-like CardAPs can improve the cardiac outcome after i.v. injection in inflammatory cardiomyopathy and addresses the direct cardiac-protective as well as systemic protective effects of MSCs/CardAPs following extra-cardiac targeting.

The capacity of MSCs to home to the site of injury/ inflammation [181, 182] is another argument in favor of the i.v. application route. In agreement, we demonstrated that the cardiac homing of endogenous MSCs in patients depends on the grade of inflammation in the heart [182]. Furthermore, the migration of MSCs from the circulation to damaged tissue leading to a therapeutic effect has already been demonstrated [183–185]. We foresee that especially a cellular therapy option for B19-induced inflammatory cardiomyopathy, which is associated with a systemic endothelial dysfunction and endothelial damage [6, 17], could profit from a systemic MSC application ensuring an endothelial engraftment.

Finally, the noninvasiveness of the i.v. administration route, avoiding all risks of transendothelial and intracoronary injections, and the ability of performing rejections make the i.v. application of MSCs an attractive therapeutic strategy. Very recent unpublished data suggest that intramuscular injection could induce systemic immunoregulatory properties protecting mice from lethal irradiation or supporting revascularization in critical limb ischemia (even if injected distant from the targeted limb). This opens a new avenue of application.

An overview of (dis)advantages of i.v., intracoronary, and endocardial MSC application for the treatment of inflammatory cardiomyopathy is given in Table 1.

### 6. Conclusion and Perspectives

In summary, it seems that MSCs do not simply inhibit cells of the immune system but rather modulate the function of a great variety of immune cells to establish a fine balance between pathogen elimination and repair processes. However, it has to be noted that many effects cannot be reproduced with all MSC types and all laboratories. The reasons for discrepancies might be the poor characterization of the MSCs used (source, species, 2D versus 3D expansion), the various age of donor (e.g. old bone marrow donors during hip replacement operation versus cord blood), and poor culture conditions (MSCs express high metabolic activities that can result in vitro in simple metabolic effects). Moreover, the mode of action of many effects is poorly understood. The coordinating signals involved in this balance remain to be elucidated, and the systemic effects of MSCs on the various immune cell types need to be extensively analyzed, particularly in view of the establishment of a physiologically immune homeostasis in inflammatory cardiomyopathy. Since the cell dose affects the amount of induced Tregs [140] as well as of lung engrafted MSCs [155] and therefore subsequent extracardiac-mediated protective effects, further studies are required clarifying the optimal MSC dose in

**Figure 2:** Hypothetical scheme representing how the cardiac outcome in inflammatory cardiomyopathy may be influenced after i.v. injection of MSCs or the MSC-like CardAPs. Via (a) direct cardioprotective effects, via (b) extracardiac immunomodulatory effects involving MSCs/CardAPs-mediated immunomodulation in the spleen and/or other secondary lymphoid organs, and the induction of tumor necrosis factor-stimulated gene- (TSG-) 6 expression by human MSCs/CardAPs upon engraftment, for example, in the lung, and via (c) systemic endothelial-protective effects. The contribution of (a), (b), or (c) on the final cardiac outcome is expected to depend on the kind of inflammatory cardiomyopathy, be it viral- (CVB3 or B19-induced) or nonviral- induced.
experimental models of inflammatory cardiomyopathy. Since so far MSCs have been shown not to be able to reduce the viral load in acute CVB3-induced myocarditis [127], despite their direct antiviral effects demonstrated in vitro [187], further studies are necessary evaluating the effect of MSC application in chronic CVB3-induced myocarditis. This investigation is also recommended for CardAPs, which did reduce the viral load in acute CVB3-induced myocarditis [86], since only in this setting it will be clear whether MSC and/or CardAPs application is not associated with viral rebound and can be used for the treatment of viral-induced inflammatory cardiomyopathy. With respect to chronic (non)viral-induced inflammatory cardiomyopathy, the impact of the time point of MSC/CardAPs application during the pathogenesis of the disorder on the cardiac outcome needs further investigation. Especially in the case of chronic inflammatory cardiomyopathy, where depending on the stage of injection, inflammation could be less prominent, and consequently the activation of MSCs could be decreased, further clarifications are required on the impact of preconditioning of the cells or of cotreatments.

Finally, the responsiveness of the patient towards the cell therapy should be estimated by analyzing the expression of chemokines and inflammation markers in the heart via the isolation of endomyocardial biopsies [188] and subsequent gene expression analysis.

These insights are still required enabling an optimal clinical application of MSCs for the treatment of inflammatory cardiomyopathy.

**Abbreviations**

| Abbreviation | Description |
|--------------|-------------|
| Breg         | Regulatory B cells |
| B7-H1        | B7 homolog 1 |
| B19          | Parvovirus B19 |
| CardAPs      | Cardiac-derived proliferating cells |
| CTL          | Cytotoxicity CD8+ T cells |
| CVB          | Coxsackievirus |
| DCM          | Dilated cardiomyopathy |
| DCs          | Dendritic cells |
| IDO          | Indoleamine 2,3-dioxygenase |
| IFN          | Interferon |
| Ig           | Immunoglobulin |
| iNOS         | Inducible nitric oxide synthase |
| IL           | Interleukin |
| i.v.         | Intravenous |
| LV           | Left ventricle |
| MSC          | Mesenchymal stromal cell |
| M1           | Classically activated macrophages |
| M2           | Alternatively activated macrophages |
| NF-κB        | Nuclear factor κB |
| NK           | Natural killer |
| PGE2         | Prostaglandin E2 |
| Th           | T helper type |
| TLR          | Toll-like receptor |
| TNF          | Tumor necrosis factor |
| TGF          | Transforming growth factor |
| Tregs        | Regulatory T cells |
| TSG-6        | Tumor necrosis factor-stimulated gene-6 |

**Conflict of Interests**

Patent holding on CardAP cells: M. Haag, J. Ringe, M. Sittinger, and C. Tschöpe.

**Acknowledgments**

This review was supported by the Berlin-Brandenburg Center for Regenerative Therapies-BCRT (Bundesministerium für Bildung und Forschung-0313911) to S. van Linthout, H.-D. Volk, and C. Tschöpe and by the SFB TR19 to C. Tschöpe. The authors would like to acknowledge the assistance of the BCRT Flow Cytometry Lab.

**References**

[1] P. Richardson, R. W. McKenna, M. Bristow et al., “Report of the 1995 World Health Organization/International Society and
Federation of Cardiology Task Force on the definition and classification of cardiomyopathies,” *Circulation*, vol. 93, no. 5, pp. 841–842, 1996.

[2] H. T. Aretz, M. E. Billingham, W. D. Edwards et al., “Myocarditis. A histopathologic definition and classification,” *The American Journal of Cardiovascular Pathology*, vol. 1, no. 1, pp. 3–14, 1987.

[3] A. M. Feldman and D. McNamara, “Myocarditis,” *The New England Journal of Medicine*, vol. 343, no. 19, pp. 1388–1398, 2000.

[4] N. E. Bowles, J. Ni, D. L. Kearney et al., “Detection of viruses in myocardial tissues by polymerase chain reaction: evidence of adenovirus as a common cause of myocarditis in children and adults,” *Journal of the American College of Cardiology*, vol. 42, no. 3, pp. 466–472, 2003.

[5] M. Pauschinger, A. Doerner, U. Kuehl et al., “Enteroviral RNA replication in the myocardium of patients with left ventricular dysfunction and clinically suspected myocarditis,” *Circulation*, vol. 99, no. 7, pp. 889–895, 1999.

[6] C. Tschöpe, C. T. Bock, M. Kasner et al., “High prevalence of cardiac parvovirus B19 infection in patients with isolated left ventricular diastolic dysfunction,” *Circulation*, vol. 111, no. 7, pp. 879–886, 2005.

[7] S. Pankuweit, R. Moll, U. Baandrup, I. Portig, G. Hufnagel, and B. Maisch, “Prevalence of the parvovirus B19 genome in endomyocardial biopsy specimens,” *Human Pathology*, vol. 34, no. 5, pp. 497–503, 2003.

[8] U. Kühl, M. Pauschinger, T. Bock et al., “Parvovirus B19 infection mimicking acute myocardial infarction,” *Circulation*, vol. 108, no. 8, pp. 945–950, 2003.

[9] A. D’Ambrosio, G. Patti, A. Manzoli et al., “The fate of acute myocarditis between spontaneous improvement and evolution to dilated cardiomyopathy: a review,” *Heart*, vol. 85, no. 5, pp. 499–504, 2001.

[10] V. L. Roger, A. S. Go, D. M. Lloyd-Jones et al., “Heart disease and stroke statistics—2011 update: a report from the American Heart Association,” *Circulation*, vol. 123, no. 4, pp. e18–e209, 2011.

[11] D. M. Lloyd-Jones, M. G. Larson, E. P. Leip et al., “Lifetime risk for developing congestive heart failure: the Framingham Heart Study,” *Circulation*, vol. 106, no. 24, pp. 3068–3072, 2002.

[12] A. Frustaci, M. A. Russo, and C. Chimenti, “Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study,” *European Heart Journal*, vol. 30, no. 16, pp. 1995–2002, 2009.

[13] B. Maisch, G. Hufnagel, S. Kölsch et al., “Treatment of inflammatory dilated cardiomyopathy and (peri)myocarditis with immunosuppression and i.v. immunoglobulins,” *Herr*, vol. 29, no. 6, pp. 624–636, 2004.

[14] “Late-Breaking Clinical Trial Abstracts,” *Circulation*, vol. 118, no. 22, pp. 2309–2317, 2008.

[15] Y. X. Wang, V. da Cunha, J. Vincelette et al., “Antiviral and myocyte protective effects of murine interferon-β and -α in coxsackievirus B3-induced myocarditis and epicarditis in Balb/c mice,” *American Journal of Physiology—Heart and Circulatory Physiology*, vol. 293, no. 1, pp. H69–H76, 2007.

[16] U. Kühl, M. Pauschinger, P. L. Schwimmbeck et al., “Interferon-β treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction,” *Circulation*, vol. 107, no. 22, pp. 2793–2798, 2003.

[17] C. Schmidt-Lucke, F. Spillmann, T. Bock et al., “Interferon beta modulates endothelial damage in patients with cardiac persistence of human parvovirus B19 infection,” *Journal of Infectious Diseases*, vol. 201, no. 6, pp. 936–945, 2010.

[18] L. A. Blauwet and L. T. Cooper, “Antimicrobial agents for myocarditis: target the pathway, not the pathogen,” *Heart*, vol. 96, no. 7, pp. 494–495, 2010.

[19] K. Le Blanc, L. Tamnik, B. Sundberg, S. E. Haynesworth, and O. Ringdén, “Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex,” *Scandinavian Journal of Immunology*, vol. 57, no. 1, pp. 11–20, 2003.

[20] M. Esfandiarei and B. M. McManus, “Molecular biology and pathogenesis of viral myocarditis,” *Annual Review of Pathology*, vol. 3, pp. 127–155, 2008.

[21] J. W. Mason, “Myocarditis and dilated cardiomyopathy an inflammatory link,” *Cardiovascular Research*, vol. 60, no. 1, pp. 5–10, 2003.

[22] I. Kindermann, M. Kindermann, R. Kadolf et al., “Predictors of outcome in patients with suspected myocarditis,” *Circulation*, vol. 118, no. 6, pp. 639–648, 2008.

[23] J. F. Woodruff and J. J. Woodruff, “Involvement of T lymphocytes in the pathogenesis of coxsackie virus B3 heart disease,” *The Journal of Immunology*, vol. 113, no. 6, pp. 1726–1734, 1974.

[24] Y. Shi, M. Fukuoka, G. Li et al., “Regulatory T cells protect mice against coxsackievirus-induced myocarditis through the transforming growth factor β-coxsackie-adenovirus receptor pathway,” *Circulation*, vol. 121, no. 24, pp. 2624–2634, 2010.

[25] K. Li, W. Xu, Q. Guo et al., “Differential macrophage polarization in male and female BALB/c mice infected with coxsackievirus B3 defines susceptibility to viral myocarditis,” *Circulation Research*, vol. 105, no. 4, pp. 353–364, 2009.

[26] J. Li, S. Leschka, S. Rutschow et al., “Immunomodulation by interleukin-4 suppresses matrix metalloproteinases and improves cardiac function in murine myocarditis,” *European Journal of Pharmacology*, vol. 554, no. 1, pp. 60–68, 2007.

[27] T. Yajima and K. U. Knowlton, “Viral myocarditis from the perspective of the virus,” *Circulation*, vol. 119, no. 19, pp. 2615–2624, 2009.

[28] D. L. Mann, “The emerging role of innate immunity in the heart and vascular system: for whom the cell tolls,” *Circulation Research*, vol. 108, no. 9, pp. 1133–1145, 2011.

[29] S. Akira and S. Sato, “Toll-like receptors and their signaling mechanisms,” *Scandinavian Journal of Infectious Diseases*, vol. 35, no. 9, pp. 555–562, 2003.

[30] Y. Seko, N. Takahashi, H. Yagita, K. Okumura, and Y. Yazaki, “Expression of cytokine mRNAs in murine hearts with acute myocarditis caused by coxsackievirus b3,” *The Journal of Pathology*, vol. 183, no. 1, pp. 105–108, 1997.

[31] K. Fuse, G. Chan, Y. Liu et al., “Myeloid differentiation factor-88 plays a crucial role in the pathogenesis of coxsackievirus B3-induced myocarditis and influences type I interferon production,” *Circulation*, vol. 112, no. 15, pp. 2276–2285, 2005.

[32] M. Satoh, M. Nakamura, T. Akatsu et al., “Expression of Toll-like receptor 4 is associated with enteroviral replication in human myocarditis,” *Clinical Science*, vol. 104, no. 6, pp. 577–584, 2003.

[33] R. Deonarain, D. Cerullo, K. Fuse, P. P. Liu, and E. N. Fish, “Protective role for interferon-β in coxsackievirus B3 infection,” *Circulation*, vol. 110, no. 23, pp. 3540–3543, 2004.
[34] U. Kühl, D. Lassner, J. von Schlippenbach, W. Poller, and H. P. Schultheiss, "Interferon-Beta improves survival in enterovirus-associated cardiomyopathy," *Journal of the American College of Cardiology*, vol. 60, no. 14, pp. 1295–1296, 2012.

[35] M. H. Hühn, M. Hultcrantz, K. Lind, H. G. Ljunggren, K. J. Malmberg, and M. Flodström-Tullberg, "IFN-gamma production dominates the early human natural killer cell response to Coxackievirus infection," *Cellular Microbiology*, vol. 10, no. 2, pp. 426–436, 2008.

[36] T. Kanda, T. Yokoyama, T. Suzuki, and K. Murata, "Functional abnormalities of circulating natural killer cell subpopulations in patients with dilated cardiomyopathy," *Tohoku Journal of Experimental Medicine*, vol. 168, no. 3, pp. 529–537, 1992.

[37] A. Matsumori, "Molecular and immune mechanisms in the pathogenesis of cardiomyopathy—role of viruses, cytokines, and nitric oxide," *Japanese Circulation Journal*, vol. 61, no. 4, pp. 275–291, 1997.

[38] B. Levine, J. Kalman, L. Mayer, H. M. Fillit, and M. Packer, "Elevated circulating levels of tumor necrosis factor in severe chronic heart failure," *New England Journal of Medicine*, vol. 323, no. 4, pp. 236–241, 1990.

[39] D. L. Mann, "Inflammatory mediators and the failing heart: past, present, and the foreseeable future," *Circulation Research*, vol. 91, no. 11, pp. 988–998, 2002.

[40] C. Ishikawa, T. Tsutamoto, M. Fujii, H. Sakai, T. Tanaka, and M. Horie, "Prediction of mortality by high-sensitivity C-reactive protein and brain natriuretic peptide in patients with dilated cardiomyopathy," *Circulation Journal*, vol. 70, no. 7, pp. 857–863, 2006.

[41] N. Jasras, U. Martin, E. Kamphausen, R. Zell, P. Wutzler, and A. Henke, "Interferon-γ-induced activation of nitric oxide-mediated antiviral activity of macrophages caused by a recombinant coxsackievirus B3," *Viral Immunology*, vol. 18, no. 2, pp. 355–364, 2005.

[42] C. J. Lowenstein, S. L. Hill, A. Lafond-Walker et al., "Nitric oxide inhibits viral replication in murine myocarditis," *Journal of Clinical Investigation*, vol. 97, no. 8, pp. 1837–1843, 1996.

[43] T. Shioi, A. Matsumori, and S. Sasayama, "Persistent expression of cytokine in the chronic stage of viral myocarditis in mice," *Circulation*, vol. 94, no. 11, pp. 2930–2937, 1996.

[44] S. Gordon and F. O. Martinez, "Alternative activation of macrophages: mechanism and functions," *Immunity*, vol. 32, no. 5, pp. 593–604, 2010.

[45] J. Banchereau and R. M. Steinman, "Dendritic cells and the control of immunity," *Nature*, vol. 392, no. 6673, pp. 245–252, 1998.

[46] A. O. Weinzierl, G. Szalay, H. Wolburg et al., "Effective chemokine secretion by dendritic cells and expansion of cross-presenting CD4−CD8+ dendritic cells define a protective phenotype in the mouse model of coxsackievirus myocarditis," *Journal of Virology*, vol. 82, no. 16, pp. 8149–8160, 2008.

[47] A. Rahnefeld, F. Ebstein, N. Albrecht et al., "Antigen-presentation capacity of dendritic cells is impaired in ongoing enterovirus myocarditis," *European Journal of Immunology*, vol. 41, no. 9, pp. 2774–2781, 2011.

[48] F. Leuschner, H. A. Katus, and Z. Kaya, "Autoimmune myocarditis: past, present and future," *Journal of Autoimmunity*, vol. 33, no. 3–4, pp. 282–289, 2009.

[49] M. A. Opavsky, J. Penninger, K. Aitken et al., "Susceptibility to myocarditis is dependent on the response of αβ T lymphocytes to coxsackieviral infection," *Circulation Research*, vol. 85, no. 6, pp. 551–558, 1999.

[50] B. Koehl, M. Oualha, F. Lesage et al., "Fatal parvovirus B19 myocarditis in children and possible dysimmune mechanism," *The Pediatric Infectious Disease Journal*, vol. 31, no. 4, pp. 418–421, 2012.

[51] L. H. Y. Young, S. V. Joag, L. M. Zheng, C. P. Lee, Y. S. Lee, and J. D. E. Young, "Perforin-mediated myocardial damage in acute myocarditis," *The Lancet*, vol. 336, no. 8722, pp. 1019–1021, 1990.

[52] Y. Koga, Y. Miyazaki, H. Toshima, H. Yori, T. Takamoto, and M. M. Yokoyama, "Lymphocyte subsets in patients with acute myopericarditis, arrhythmias and dilated cardiomyopathy," *Japanese Circulation Journal*, vol. 53, no. 1, pp. 78–86, 1989.

[53] E. Lindberg, B. Andersson, E. H. Hörnquist, and Y. Magnusson, "Impaired activation of IFN-γ CD4+ T cells in peripheral blood of patients with dilated cardiomyopathy," *Cellular Immunology*, vol. 263, no. 2, pp. 224–229, 2010.

[54] R. T. Gazzinelli, M. Wysocka, S. Hieny et al., "In the absence of endogenous IL-10, mice acutely infected with Toxoplasma gondii succumb to a lethal immune response dependent on CD4+ T cells and accompanied by overproduction of IL-12, IFN-γ, and TNF-α," *Journal of Immunology*, vol. 157, no. 2, pp. 798–805, 1996.

[55] Y. Li, J. S. Heuser, S. D. Kongsan, M. Hemric, and M. W. Cunningham, "Protection against experimental autoimmune myocarditis is mediated by interleukin-10-producing T cells that are controlled by dendritic cells," *American Journal of Pathology*, vol. 167, no. 1, pp. 5–15, 2005.

[56] L. Gullestad, H. Aass, J. G. Fjeld et al., "Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure," *Circulation*, vol. 103, no. 2, pp. 220–225, 2001.

[57] M. Afanasyeva, Y. Wang, Z. Kaya et al., "Interleukin-12 receptor/STAT4 signaling is required for the development of autoimmune myocarditis in mice by an interferon-γ-independent pathway," *Circulation*, vol. 104, no. 5, pp. 3145–3151, 2001.

[58] U. Eriksson, M. O. Kurre, W. Sebald, F. Brombacher, and M. Kopf, "Dual role of the IL-12/IFN-γ axis in the development of autoimmune myocarditis: induction by IL-12 and protection by IFN-γ," *Journal of Immunology*, vol. 167, no. 9, pp. 5464–5469, 2001.

[59] Z. Wang, J. Hong, W. Sun et al., "Role of IFN-γ in induction of Foxp3 and conversion of CD4+CD25− T cells to CD4+ Tregs," *Journal of Clinical Investigation*, vol. 116, no. 9, pp. 2434–2441, 2006.

[60] D. Fairweather, S. Frisancho-Kiss, S. A. Yusung et al., "Interferon-γ protects against chronic viral myocarditis by reducing mast cell degranulation, fibrosis, and the profibrotic cytokines transforming growth factor-β1, interleukin-1β, and interleukin-4 in the heart," *American Journal of Pathology*, vol. 165, no. 6, pp. 1883–1894, 2004.

[61] M. Afanasyeva, D. Georgakopoulos, D. F. Belardi et al., "Impaired up-regulation of CD25 on CD4+ T cells in IFN-γ knockout mice is associated with progression of myocarditis to heart failure," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 102, no. 1, pp. 180–185, 2005.

[62] K. C. Huber, B. J. Gersh, D. D. Sugrue, R. L. Frye, K. R. Bailey, and R. E. Ritts, "T-lymphocyte subsets in patients with idiopathic dilated cardiomyopathy," *International Journal of Cardiology*, vol. 22, no. 1, pp. 59–66, 1989.

[63] M. J. McGeachy and D. J. Cua, "Th17 cell differentiation: the long and winding road," *Immunity*, vol. 28, no. 4, pp. 445–453, 2008.
D. Mougiakakos, R. Jitschin, C. C. Johansson, R. Okita, R. Kiessling, and K. Le Blanc, “The impact of inflammatory licensing on heme oxygenase-1-mediated induction of regulatory T cells by human mesenchymal stem cells,” Blood, vol. 117, no. 18, pp. 4826–4835, 2011.

H. Choi, R. H. Lee, N. Bazhanov, J. Y. Oh, and D. J. Prockop, “Anti-inflammatory protein TSG-6 secreted by activated MSCs attenuates zymosan-induced mouse peritonitis by decreasing TLR2/NF-kB signaling in resident macrophages,” Blood, vol. 118, no. 2, pp. 330–338, 2011.

L. A. Ortiz, M. DuTreil, C. Fattman et al., “Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 26, pp. 10002–10007, 2007.

M. H. Hühn, M. Hultcrantz, K. Lind, H. G. Ljunggren, K. J. Malmberg, and M. Flodström-Tullberg, “IFN-γ production dominates the early human natural killer cell response to Coxsackievirus infection,” Cellular Microbiology, vol. 10, no. 2, pp. 426–436, 2008.

G. M. Spaggiari, A. Capobianco, H. Abdelrazik, F. Becchetti, M. C. Mingari, and L. Moretta, “Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxigenase and prostaglandin E2,” Blood, vol. 111, no. 3, pp. 1327–1333, 2008.

I. Rasmusson, O. Ringdén, B. Sundberg, and K. Le Blanc, “Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells,” Transplantation, vol. 76, no. 8, pp. 1208–1213, 2003.

A. Poggi, C. Prevosto, A. M. Massaro et al., “Interaction between human NK cells and bone marrow stromal cells induces NK cell triggering: role of NKp30 and NKG2D receptors,” Journal of Immunology, vol. 175, no. 10, pp. 6352–6360, 2005.

G. M. Spaggiari, A. Capobianco, S. Becchetti, M. C. Mingari, and L. Moretta, “Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation,” Blood, vol. 107, no. 4, pp. 1484–1490, 2006.

S. A. Patel, J. R. Meyer, S. J. Greco, K. E. Corcoran, M. Bryan, and P. Rameshwar, “Mesenchymal stem cells protect breast cancer cells through regulatory T cells: role of mesenchymal stem cell-derived TGF-β,” Journal of Immunology, vol. 184, no. 10, pp. 5885–5894, 2010.

P. A. Sotiropoulou, S. A. Perez, A. D. Gritzapis, C. N. Baxevanis, and M. Papamichail, “Interactions between human mesenchymal stem cells and natural killer cells,” Stem Cells, vol. 24, no. 1, pp. 74–85, 2006.

S. Aggarwal and M. F. Pittenger, “Human mesenchymal stem cells modulate allogeneic immune cell responses,” Blood, vol. 105, no. 4, pp. 1815–1822, 2005.

J. Yuan, Z. Liu, T. Lim et al., “CXCL10 inhibits viral replication through recruitment of natural killer cells in coxsackievirus B3-induced myocarditis,” Circulation Research, vol. 104, no. 5, pp. 628–638, 2009.

S. O. Daniela Cihakova, “Natural killer cells suppress cardiac eosinophilia in autoimmune myocarditis,” The Journal of Immunology, vol. 188, article 171, 21, 2012.

H. Koike, T. Kanda, H. Sumino et al., “Reduction of viral myocarditis in mice lacking perforin,” Research Communications in Molecular Pathology and Pharmacology, vol. 110, no. 3–4, pp. 229–237, 2001.

L. Chen, W. Zhang, H. Yue et al., “Effects of human mesenchymal stem cells on the differentiation of dendritic cells from CD34+ cells,” Stem Cells and Development, vol. 16, no. 5, pp. 719–731, 2007.

Z. J. Jiang, W. Xu, K. Li et al., “Remission of CVB3-induced viral myocarditis by in vivo Th2 polarization via hydrodynamics-based interleukin-4 gene transfer,” Journal of Gene Medicine, vol. 10, no. 8, pp. 918–929, 2008.

E. D. Abston, M. J. Coronado, A. Bucek et al., “Th2 regulation of viral myocarditis in mice: different roles for TLR3 versus TRIF in progression to chronic disease,” Clinical and Developmental Immunology, vol. 2012, Article ID 129486, 12 pages, 2012.

W. Zhang, W. Ge, C. Li et al., “Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells,” Stem Cells and Development, vol. 13, no. 3, pp. 263–271, 2004.

R. Ramasamy, H. Fazekasova, E. W. F. Lam, I. Soeiro, G. Lombardi, and F. Dazzi, “Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle,” Transplantation, vol. 83, no. 1, pp. 71–76, 2007.

R. Maccario, M. Podestà, A. Moreta et al., “Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype,” Haematologica, vol. 90, no. 4, pp. 516–525, 2005.

S. Chiesa, S. Morbelli, S. Morando et al., “Mesenchymal stem cells impair in vivo T-cell priming by dendritic cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 42, pp. 17384–17389, 2011.

S. S. Ahuja, C. A. Estrada, and M. L. Lindsey, “Crosstalk between cytotoxic T-lymphocyte-associated antigen-4 and interleukin-12 in cytotoxic T-lymphocyte-mediated myocarditis: adding another link to the chain,” Circulation Research, vol. 101, no. 3, pp. 218–220, 2007.

A. Bartholomew, C. Sturgeon, M. Siatskas et al., “Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo,” Experimental Hematology, vol. 30, no. 1, pp. 42–48, 2002.

W. T. Tse, J. D. Pendleton, W. M. Beyer, M. C. Egalka, and E. C. Guinan, “Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation,” Transplantation, vol. 75, no. 3, pp. 389–397, 2003.

R. Meisel, A. Zibert, M. Laryea, U. Göbel, W. Däubener, and D. Dilloo, “Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxigenase-mediated tryptophan degradation,” Blood, vol. 103, no. 12, pp. 4619–4621, 2004.

E. Zappia, S. Casazza, E. Pedemonte et al., “Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy,” Blood, vol. 106, no. 5, pp. 1755–1761, 2005.

I. Rasmusson, O. Ringdén, B. Sundberg, and K. Le Blanc, “Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms,” Experimental Cell Research, vol. 305, no. 1, pp. 33–41, 2005.

M. Kramerpa, S. Glennie, J. Dyson et al., “Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide,” Blood, vol. 101, no. 9, pp. 3722–3729, 2003.

S. Glennie, I. Soeiro, P. J. Dyson, E. W. F. Lam, and F. Dazzi, “Bone marrow mesenchymal stem cells induce division arrest...
nergy of activated T cells,” *Blood*, vol. 105, no. 7, pp. 2821–2827, 2005.

[126] K. Akiyama, C. Chen, D. Wang et al., “Mesenchymal-stem-cell-induced immunoregulation involves FAS-ligand-/FAS-mediated T cell apoptosis,” *Cell Stem Cell*, vol. 10, no. 5, pp. 544–555, 2012.

[127] K. Savvatis, S. van Lintouth, K. Miteva et al., “Mesenchymal stromal cells but not cardiac fibroblasts exert beneficial systemic immunomodulatory effects in experimental myocarditis,” *PLoS ONE*, vol. 7, no. 7, article e41047, 2012.

[128] C. Bouffi, C. Bony, G. Courties, C. Jorgensen, and D. Noel, “IL-6-dependent PGE2 secretion by mesenchymal stem cells inhibits local inflammation in experimental arthritis,” *PLoS ONE*, vol. 5, no. 12, article e14247, 2010.

[129] Q. F. Kong, B. Sun, S. S. Bai et al., “Administration of bone marrow stromal cells ameliorates experimental autoimmune myasthenia gravis by altering the balance of Th1/Th2/Th17/Treg cell subsets through the secretion of TGF-β,” *Journal of Neuroimmunology*, vol. 207, no. 1-2, pp. 83–91, 2009.

[130] W. Zhao, Y. Wang, D. Wang et al., “TGF-β expression by allogeneic bone marrow stromal cells ameliorates diabetes in NOD mice through modulating the distribution of CD4+ T cell subsets,” *Cellular Immunology*, vol. 253, no. 1-2, pp. 23–30, 2008.

[131] A. Henke, R. Zell, U. Martin, and A. Stelzner, “Direct interferon-γ-mediated protection caused by a recombinant coxsackievirus B3,” *Virology*, vol. 315, no. 2, pp. 335–344, 2003.

[132] M. K. Levings, R. Bacchetta, U. Schulz, and M. G. Roncarolo, “The role of IL-10 and TGF-beta in the differentiation and effector function of T regulatory cells,” *International Archives of Allergy and Immunology*, vol. 129, no. 4, pp. 263–276, 2002.

[133] K. J. Wood and B. Sawitzi, “Interferon gamma: a crucial role in the function of induced regulatory T cells in vivo,” *Trends in Immunology*, vol. 27, no. 4, pp. 183–187, 2006.

[134] L. Bai, D. P. Lennon, V. Eaton et al., “Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis,” *Glia*, vol. 57, no. 11, pp. 1192–1209, 2009.

[135] S. Ghannam, J. P`ene, G. Torcy-Moquet, C. Jorgensen, and H. Yssel, “Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype,” *Journal of Immunology*, vol. 185, no. 1, pp. 302–312, 2010.

[136] M. M. Duffy, J. Pindjakova, S. A. Hanley et al., “Mesenchymal stem cell inhibition of T-helper 17 cell differentiation is triggered by cell-cell contact and mediated by prostaglandin E2 via the EP4 receptor,” *European Journal of Immunology*, vol. 41, no. 10, pp. 2840–2851, 2011.

[137] F. Casiraghi, N. Azzollini, P. Cassis et al., “Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells,” *Journal of Immunology*, vol. 181, no. 6, pp. 3933–3946, 2008.

[138] Y. Wang, A. Zhang, Z. Ye, H. Xie, and S. Zheng, “Bone marrow-derived mesenchymal stem cells inhibit acute rejection of rat liver allografts in association with regulatory T-cell expansion,” *Transplantation Proceedings*, vol. 41, no. 10, pp. 4352–4356, 2009.

[139] W. Ge, J. Jiang, M. L. Baroja et al., “Infusion of mesenchymal stem cells and rapamycin synergize to attenuate alloimmune responses and promote cardiac allograft tolerance,” *American Journal of Transplantation*, vol. 9, no. 8, pp. 1760–1772, 2009.

[140] H. Kavanagh and B. P. Mahon, “Allogeneic mesenchymal stem cells prevent allergic airway inflammation by inducing murine regulatory T cells,” *Allergy*, vol. 66, no. 4, pp. 523–531, 2011.

[141] M. Rafei, P. M. Campeau, A. Aguilar-Mahecha et al., “Mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a C57Bl/6J background,” *Journal of Immunology*, vol. 182, no. 10, pp. 5994–6002, 2009.

[142] Z. Selmani, A. Naji, I. Zidi et al., “Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+ CD25HighFOXP3+ regulatory T cells,” *Stem Cells*, vol. 26, no. 1, pp. 212–222, 2008.

[143] K. English, J. M. Ryan, L. Tobin, M. J. Murphy, F. P. Barry, and B. P. Mahon, “Cell contact, prostaglandin E2 and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25Highforkhead box P3+ regulatory T cells,” *Clinical and Experimental Immunology*, vol. 156, no. 1, pp. 149–160, 2009.

[144] W. Ge, J. Jiang, J. Arp, W. Liu, B. Garcia, and H. Wang, “Regulatory T-cell generation and kidney allograft tolerance induced by mesenchymal stem cells associated with indoleamine 2,3-dioxygenase expression,” *Transplantation*, vol. 90, no. 12, pp. 1312–1320, 2010.

[145] F. C. Popp, E. Eggenhofer, P. Renner et al., “Mesenchymal stem cells can induce long-term acceptance of solid organ allografts in synergy with low-dose mycophenolate,” *Transplant Immunology*, vol. 20, no. 1-2, pp. 55–60, 2008.

[146] A. M. Madec, R. Mallone, G. Afonso et al., “Mesenchymal stem cells protect NOD mice from diabetes by inducing regulatory T cells,” *Diabetologia*, vol. 52, no. 7, pp. 1391–1399, 2009.

[147] Q. Zhang, S. Shi, Y. Liu et al., “Mesenchymal stem cells derived from human gingiva are capable of immunomodulatory functions and ameliorate inflammation-related tissue destruction in experimental colitis,” *Journal of Immunology*, vol. 183, no. 12, pp. 7778–7798, 2009.

[148] K. Nemeth, A. Keane-Myers, J. M. Brown et al., “Bone marrow stromal cells use TGF-beta to suppress allergic responses in a mouse model of ragweed-induced asthma,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 107, no. 12, pp. 5652–5657, 2010.

[149] H. Sheng, Y. Wang, Y. Jin et al., “A critical role of IFNγ in priming MSC-mediated suppression of T cell proliferation through up-regulation of B7-H1,” *Cell Research*, vol. 18, no. 8, pp. 846–857, 2008.

[150] M. Kramerpera, L. Cosmi, R. Angeli et al., “Role for interferon-γ in the immunomodulatory activity of human bone marrow mesenchymal stem cells,” *Stem Cells*, vol. 24, no. 2, pp. 386–398, 2006.

[151] J. M. Ryan, F. Barry, I. M. Murphy, and B. P. Mahon, “Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells,” *Clinical & Experimental Immunology*, vol. 149, no. 2, pp. 353–363, 2007.

[152] M. D. Nicola, C. Carlo-Stella, M. Magni et al., “Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli,” *Blood*, vol. 99, no. 10, pp. 3838–3843, 2002.

[153] D. Chabannes, M. Hill, E. Merieau et al., “A role for heme oxygenase-1 in the immunosuppressive effect of adult rat and human mesenchymal stem cells,” *Blood*, vol. 110, no. 10, pp. 3691–3694, 2007.
[154] F. Morandi, L. Raffaghello, G. Bianchi et al., “Immunogenicity of human mesenchymal stem cells in HLA-class I-restricted T-cell responses against viral or tumor-associated antigens,” Stem Cells, vol. 26, no. 5, pp. 1275–1287, 2008.

[155] R. H. Lee, A. A. Pulin, M. J. Seo et al., “Intravenous hMSCs improve myocardial infarction in mice because cells engrafted in lung are activated to secrete the anti-inflammatory protein TSG-6,” Cell Stem Cell, vol. 5, no. 1, pp. 54–63, 2009.

[156] N. A. Mitchison and L. R. Wedderburn, “B cells in autoimmunity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 16, pp. 8750–8751, 2000.

[157] R. H. Lee, A. A. Pulin, M. J. Seo et al., “Intravenous hMSCs reduce inflammatory damage to the cornea without engraftment and primarily by secretion of TNF-α stimulated gene/protein 6,” Stem Cells, vol. 29, no. 10, pp. 1572–1579, 2011.

[158] G. W. Roddy, J. Y. Oh, R. H. Lee et al., “Action at a distance: systemically administered adult stem/progenitor cells (MSCs) reduce inflammatory damage to the cornea without engraftment and primarily by secretion of TNF-α stimulated gene/protein 6,” Stem Cells, vol. 29, no. 10, pp. 1572–1579, 2011.

[159] F. Leuschner, P. Panizzi, I. Chico-Calero et al., “Angiotensin receptor agonists,” Cell Stem Cell, vol. 2, no. 2, pp. 207–216, 2008.

[160] S. Tomic, J. Djokic, S. Vasilijic et al., “Immunomodulatory properties of mesenchymal stem cells derived from dental pulp and dental follicle are susceptible to activation by Toll-like receptor agonists,” Stem Cells and Development, vol. 20, no. 4, pp. 695–708, 2011.

[161] G. Raicevic, R. Rouas, M. Najar et al., “Inflammation modifies the pattern and the function of Toll-like receptors expressed by human mesenchymal stromal cells,” Human Immunology, vol. 71, no. 3, pp. 235–244, 2010.
[185] E. M. Horwitz, P. L. Gordon, W. K. K. Koo et al., “Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 99, no. 13, pp. 8932–8937, 2002.

[186] Y. Wang, Z. B. Han, J. Ma et al., “A toxicity study of multiple-dose administration human umbilical cord mesenchymal stem cells in cynomolgus monkeys,” *Stem Cells and Development*, vol. 21, no. 9, pp. 1401–1408, 2012.

[187] S. van Linthout, K. Savvatis, K. Miteva et al., “Mesenchymal stem cells improve murine acute coxsackievirus B3-induced myocarditis,” *European Heart Journal*, vol. 32, no. 17, pp. 2168–2178, 2011.

[188] H. P. Schultheiss, U. Kühl, and L. T. Cooper, “The management of myocarditis,” *European Heart Journal*, vol. 32, no. 21, pp. 2616–2625, 2011.